89793-83-9 Usage
Uses
Used in Pharmaceutical Industry:
6-nitrobenzo[d]isoxazol-3-amine is used as a precursor in the synthesis of pharmaceutical compounds. Its unique structure and reactivity make it a valuable building block for the development of new drugs.
Used in Agrochemical Industry:
6-nitrobenzo[d]isoxazol-3-amine is used as a precursor in the synthesis of agrochemicals. Its potential reactivity and functional groups can be utilized to create new agrochemicals with improved properties.
Used in Organic Synthesis:
6-nitrobenzo[d]isoxazol-3-amine is used as a reactive intermediate in organic synthesis. Its nitro and amine groups can participate in various chemical reactions, enabling the formation of a wide range of organic compounds.
Used in Enzyme Inhibition Research:
6-nitrobenzo[d]isoxazol-3-amine has been studied for its potential pharmacological properties, including its activity as an inhibitor of certain enzymes. Its unique structure and reactivity make it a promising candidate for the development of enzyme inhibitors.
Used in Material Science:
6-nitrobenzo[d]isoxazol-3-amine may have applications in the development of novel materials. Its heterocyclic structure and functional groups can be utilized to create new materials with unique properties and potential applications in various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 89793-83-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,9,7,9 and 3 respectively; the second part has 2 digits, 8 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 89793-83:
(7*8)+(6*9)+(5*7)+(4*9)+(3*3)+(2*8)+(1*3)=209
209 % 10 = 9
So 89793-83-9 is a valid CAS Registry Number.
89793-83-9Relevant academic research and scientific papers
FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES
-
Page/Page column 163, (2020/09/30)
The present application relates to compounds according to Formula (I), pharmaceutical compositions comprising at least one of said compounds, their use as a medicament, and their use in treating chronic hepatitis B virus (HBV) infection. The disclosure further pertains to methods for preparing compounds according to Formula (I).
COMPOUNDS FOR TREATMENT OF CARDIAC ARRHYTHMIAS AND HEART FAILURE
-
Page/Page column 7, (2019/10/19)
This disclosure concerns compounds and a method for modulating the activity of calcium ion channels, including Ca2+-induced (or Ca2+-activated) calcium release channels and conformationally coupled calcium release channels such as ryanodine receptors. Some of the compounds have a structure according to formula I, or a stereoisomer, tautomer, hydrate, solvate, prodrug, or pharmaceutically acceptable salt thereof.
